MAOA: Amine oxidase [flavin-containing] A
Catalyzes the oxidative deamination of primary and some secondary amine such as neurotransmitters, with concomitant reduction of oxygen to hydrogen peroxide and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues.
- Drugs that act on it: 5
- Approved: 4
- In phases 1 to 3: 1
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on MAOA, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 4
- Other 1
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- AstraZeneca Pharmaceuticals120%
- Vernalis (R&D) Ltd120%
| MinaprineWithdrawn | Approved | AstraZeneca Pharmaceuticals | Small molecule | Inhibitor | 1 |
| Moclobemide | Approved | — | Small molecule | Inhibitor | 1 |
| ProxibarbalWithdrawn | Approved | — | Small molecule | ActivatorMonoamine oxidase A activator | 0 |
| Toloxatone | Approved | — | Small molecule | Inhibitor | 0 |
| Indantadol | Phase 2 | Vernalis (R&D) Ltd | Other | Inhibitor | 0 |
| A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | Minaprine | Phase 2 | Active, not recruiting | AstraZeneca | Jan 27, 2025 |
| Efficacy of Hydroxyzine for Patients With Panic Disorder | Moclobemide | Phase 4 | Not yet recruiting | Sultan Qaboos University | Feb 21, 2023 |
- Brunner syndrome0.79
- Major depressive disorder0.61
- Depressive disorder0.54
- Hypertensive disorder0.46
- Hereditary disease0.45
- Mental disorder0.38
- Melancholia0.37
- Autism0.34
- Intellectual disability0.31
- Drooling0.26
- Internet addiction disorder0.11
- Posterior cortical atrophy0.11
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1951, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P21397, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets